#ShortHer - Twitter Hashtag

over 1 year ago

📢 #ShortHER 10-year survival data and TILs! First study showing prognostic role of TILs on OS in HER2+ early BC. Patients with TILs≥20% did not show any additional risk with shorter trastuzumab duration. #bcsm @OncoAlert @vitti10 @UniPadova https://t.co/Y15rXY5Gfk

1

30

9

6

2K

Paolo Tarantino

@PTarantinoMD

over 1 year ago

Interesting sub-analysis of the #ShortHER trial by @vitti10 et al published on @JAMAOnc. Baseline TILs significantly impact prognosis in HER2+ eBC, and patients with more immunogenic tumors seem to have similar outcomes with less intensive adj regimens. https://t.co/oT0OcKAXJg

PTarantinoMD's tweet photo. Interesting sub-analysis of the #ShortHER trial by @vitti10 et al published on @JAMAOnc. Baseline TILs significantly impact prognosis in HER2+ eBC, and patients with more immunogenic tumors seem to have similar outcomes with less intensive adj regimens. https://t.co/oT0OcKAXJg https://t.co/FSsmjhsnrb

0

48

14

11

4K

Dr Efren Bolivar Abreu, MD, PhD @efrenbolivar

over 5 years ago

Updated results from the #ShortHER randomised trial comparing 9 weeks vs 1 year of adjuvant #trastuzumab in patients with #HER2+ early #BreastCancer presented at #ESMOBreast21 @myESMO @OncoAlert #bcsm via @matteolambe

Matteo Lambertini, MD PhD @matteolambe

over 5 years ago

Updated results from the #ShortHER randomised trial comparing 9 weeks vs 1 year of adjuvant #trastuzumab in patients with #HER2+ early #BreastCancer presented at #ESMOBreast21 @myESMO @OncoAlert #bcsm

matteolambe's tweet photo. Updated results from the #ShortHER randomised trial comparing 9 weeks vs 1 year of adjuvant #trastuzumab in patients with #HER2+ early #BreastCancer presented at #ESMOBreast21

@myESMO @OncoAlert #bcsm https://t.co/EVP1ZkfbTW

0

92

30

3

0

3

0

Kevin Punie @kevinpunie

over 5 years ago

#ESMOBreast21 Great discussion putting the data of the first Best abstracts session into context by @E_de_Azambuja #ShortHER @myESMO @OncoAlert #bcsm @mybsmo

kevinpunie's tweet photo. #ESMOBreast21
Great discussion putting the data of the first Best abstracts session into context by @E_de_Azambuja
#ShortHER
@myESMO @OncoAlert #bcsm @mybsmo https://t.co/yZDLBTFE4C

1

14

3

0

Abeid Athman (Omar). @bin_abeid

over 5 years ago

De-escalation of Trastuzumab seems a great option for low risk HER2 positive BC patients according to the final analysis of #ShortHER trial presented in #ESMOBreast21 by Prof. Conte @curijoey

bin_abeid's tweet photo. De-escalation of Trastuzumab seems a great option for low risk HER2 positive BC patients according to the final analysis of #ShortHER trial presented in #ESMOBreast21 by Prof. Conte @curijoey https://t.co/s2021UFTz7

0

7

1

0

Matteo Lambertini, MD PhD @matteolambe

over 5 years ago

Updated results from the #ShortHER randomised trial comparing 9 weeks vs 1 year of adjuvant #trastuzumab in patients with #HER2+ early #BreastCancer presented at #ESMOBreast21 @myESMO @OncoAlert #bcsm

0

92

30

3

0

Erika Hamilton, MD, FASCO @ErikaHamilton9

over 5 years ago

Long term outcomes of #ShortHER- 9 wks vs. 1 yr adj trastuzumab 8 yr f/u: 📍no diff in DFS (HR 1.09), 80% DFS long vs. 78.3% short arm ❤️ long course ⬆️ cardiac events 💡 no diff for low/int risk categories but BENEFIT for long H in high risk #ESMOBreast21 @OncoAlert